Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00258232 · ClinicalTrials.gov registry record · Phase 2
Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00258232: Completed Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT00258232 is a Phase 2 study that has completed, run by Barbara Ann Karmanos Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00258232, a Phase 2 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving celecoxib together with capecitabine and irinotecan may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving celecoxib together with capecitabine and irinotecan works in treating patients with recurrent or metastatic colorectal cancer.
Interventions
- DRUG capecitabine
- DRUG irinotecan hydrochloride
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-01 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
What the finished NCT00258232 record still lists
NCT00258232 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which capecitabine is the first listed.
NCT00258232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00258232 about?
NCT00258232 is a clinical study titled "Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer". RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Gi...
What is the current status of trial NCT00258232?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-01. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00258232?
The interventions under investigation include: capecitabine (DRUG), irinotecan hydrochloride (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00258232?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia